PTO/SB08A/B (04-03) Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 1

SHEET

	LETE IF KNOWN
Application Number	09/694,519
Confirmation Number	9641
Filing Date	10/23/2000
First Named Inventor	Robert J. Isfort
Group Art Unit	1637
Examiner Name	Teresa E. Strzelecka
Attorney Docket Number	8311

U. S. PATENT DOCUMENTS

EXAMINER	Cite	DOCUMENT NUMBER			Pages, Columns, Lines Where
INITIALS*	No.'		Publication Date	Name of Patentee or Applicant of	Relevant Passages or Relevant
		Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Figures Appear
_ 27	V 1	US-6,114,127	09/05/2000	Bergsma et al.	
		US-			•

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT				Pages, Columns, Lines	
EXAMINER INITIALS*	Cite No.1	Country Code ³ Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁴
27	√2	WO 95/06724		03/09/1995	Medical Research Council		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1						
12,	GOURLET, P. et al., "The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP ₂ Receptor Subclass", Peptides, 1996, Vol. 18, pp. 403-408.						
	/4	WEI, Y. et al., "Tissue Specific Expression of Different Human Receptor Types for Pituitary Adenylate Cyclase Activating Polypeptide and Vasoactive Intestinal Polypeptide: Implications for their Role in Human Physiology", J. of Neuroendocrinology, 1996, Vol. 8, pp. 811-817.					
	5	ADAMOU, J.E. et al., "Cloning and functional Characterization of the Human Vasoactive Intestinal Peptide (VIP)-2 Receptor", <u>Biochemical and Biophysical Research Communications</u> , 1995, Vol. 209, No. 2, pp. 385-392.					
	/ 6	GOURLET, P. et al., "Development of High Affinity Selective VIP ₁ Receptor Agonists", <u>Peptides</u> , 1997, Vol. 18, No. 10, pp. 1539-1545.					
12	√ 7	IGUCHI, G. et al., "Cloning and characterization of the 5'-Flanking Region of the Human Growth Hormone-releasing Hormone Receptor Gene", <u>J. of Biological Chem.</u> , 1999, Vol. 274, No. 17, pp. 12108-12114.					
EXAMINE	 R	Teresa Structuca DATE CONSIDERED 12/16/03					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TECH CENTER 1600/2000